Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Oncol Ther. 2024 Mar;12(1):13-17. doi: 10.1007/s40487-023-00249-0. Epub 2023 Nov 14.

Heidi Ko¹, Rebecca A Previs^{2

3}, Kyle C Strickland^{2

4}, Jonathan Klein², Brian Caveney², Chiara Chiruzzi⁵, Marcia Eisenberg², Eric A Severson², Shakti Ramkissoon^{2

6}, Kamal S Saini^{7

8}

¹ Labcorp Oncology, Durham, NC, 27560, USA. Heidi.Ko@labcorp.com.
² Labcorp Oncology, Durham, NC, 27560, USA.
³ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
⁴ Department of Pathology, Duke University Medical Center, Duke Cancer Institute, Durham, NC, 27710, USA.
⁵ Fortrea Inc, Durham, NC, USA.
⁶ Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, 27109, USA.
⁷ Fortrea Inc, Durham, NC, USA. kamalveer.saini@fortrea.com.
⁸ Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. kamalveer.saini@fortrea.com.

No abstract available

Keywords: HER2 testing; HER2-directed antibody–drug conjugate; HER2-low; Metastatic breast cancer.

Publication types